Breaking News Instant updates and real-time market news.

MRK

Merck

$62.09

0.57 (0.93%)

07:01
10/19/16
10/19
07:01
10/19/16
07:01

Merck says Phase 3 letermovir study met primary endpoint

Merck & Co. announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. The global, multicenter, randomized, placebo-controlled study evaluated the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus infection in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant. Merck will submit results from the study for presentation at a future scientific conference. In the study, letermovir was administered once daily, either in oral tablet or IV formulation. Letermovir was started as early as the day of HSCT transplant and no later than 28 days post-transplant, and continued through approximately 100 days after transplant. The primary outcome measure was the percentage of participants with clinically-significant CMV infection through 24 weeks after transplant. Under an agreement signed in 2012, Merck purchased worldwide rights to develop and commercialize letermovir from AiCuris GmbH & Co KG.

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 06

    Nov

  • 11

    Nov

MRK Merck
$62.09

0.57 (0.93%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/13/16
BOFA
10/13/16
UPGRADE
Target $70
BOFA
Buy
Merck upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Colin Bristow upgraded Merck to Buy and raised its price target to $70 from $57 to reflect its opportunity in first line lung cancer. Bristow significantly raised his Keytruda sales estmate to 7.5B from $5.5B following Merck's first line lung cancer data presentations at ESMO over the weekend and feedback from experts. He expects Keytruda to receive early approval/launch in first line NSCLC from the December 24 PDUFA and to become the standard of care in the identified label and further upside from chemo combo.
10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ACN

Accenture

$121.23

0.51 (0.42%)

15:17
02/20/17
02/20
15:17
02/20/17
15:17
Hot Stocks
Accenture announces intent to acquire SinnerSchrader »

Accenture announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGG

CGG SA

15:13
02/20/17
02/20
15:13
02/20/17
15:13
Hot Stocks
CGG SA says secures consent from debt holders »

CGG SA CGG announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PI

Impinj

$31.17

-4.19 (-11.85%)

15:05
02/20/17
02/20
15:05
02/20/17
15:05
Hot Stocks
Impinj announces partnership, platform integration with STANLEY Healthcare »

Impinj announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

HRS

Harris

$109.46

0.81 (0.75%)

15:03
02/20/17
02/20
15:03
02/20/17
15:03
Hot Stocks
Harris wins $189M contract with UAE military »

Harris has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$100.52

-0.3 (-0.30%)

15:01
02/20/17
02/20
15:01
02/20/17
15:01
Hot Stocks
Alibaba announces strategic partnership with Bailian Group »

Alibaba and Chinese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 19

    Mar

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

, VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

14:58
02/20/17
02/20
14:58
02/20/17
14:58
Hot Stocks
Sierra Wireless says connected car products selected by Volkswagen »

Sierra Wireless (SWIR)…

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$10.62

0.08 (0.76%)

, CLMS

Calamos

$8.24

-0.03 (-0.36%)

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Progenics to replace Calamos in S&P 600 as of 2/20 close »

Calamos Asset Management…

PGNX

Progenics

$10.62

0.08 (0.76%)

CLMS

Calamos

$8.24

-0.03 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 01

    Mar

SFLY

Shutterfly

$48.06

0.66 (1.39%)

, VASC

Vascular Solutions

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Shutterfly to replace Vascular Solutions in S&P 600 as of 2/20 close »

S&P MidCap 400…

SFLY

Shutterfly

$48.06

0.66 (1.39%)

VASC

Vascular Solutions

TFX

Teleflex

$179.91

1.86 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NKTR

Nektar

$13.10

0.12 (0.92%)

, BMY

Bristol-Myers

$54.59

0.31 (0.57%)

14:48
02/20/17
02/20
14:48
02/20/17
14:48
Hot Stocks
Nektar reports Phase 1 data on NKTR-214 in kidney cancer »

Nektar Therapeutics…

NKTR

Nektar

$13.10

0.12 (0.92%)

BMY

Bristol-Myers

$54.59

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

XNCR

Xencor

$24.28

0.5 (2.10%)

14:38
02/20/17
02/20
14:38
02/20/17
14:38
Hot Stocks
Xencor announces data presentation on XmAb5871 »

Xencor announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

RHHBY

Roche

$30.53

0.02 (0.07%)

14:35
02/20/17
02/20
14:35
02/20/17
14:35
Hot Stocks
Genentech reports Phase 2 data on Tecentriq combo in kidney cancer »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 09

    Mar

  • 26

    Jun

RVSB

Riverview Bancorp

$7.50

-0.11 (-1.45%)

14:30
02/20/17
02/20
14:30
02/20/17
14:30
Hot Stocks
Breaking Hot Stocks news story on Riverview Bancorp »

Riverview Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCN

Ocwen

$5.24

0.09 (1.75%)

14:27
02/20/17
02/20
14:27
02/20/17
14:27
Hot Stocks
Ocwen reaches settlement, termination of California consent order »

Ocwen Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SYF

Synchrony

$36.68

-0.17 (-0.46%)

14:07
02/20/17
02/20
14:07
02/20/17
14:07
Periodicals
Synchrony likely to see more gains, Barron's says »

Synchrony "still has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$160.25

-3.52 (-2.15%)

, CI

Cigna

$143.56

-1.77 (-1.22%)

14:05
02/20/17
02/20
14:05
02/20/17
14:05
Periodicals
Merger collapse could get Anthem back on track, Barron's says »

The likely collapse of…

ANTM

Anthem

$160.25

-3.52 (-2.15%)

CI

Cigna

$143.56

-1.77 (-1.22%)

ESRX

Express Scripts

$69.97

0.74 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

, PLKI

Popeyes

$66.12

-0.26 (-0.39%)

13:50
02/20/17
02/20
13:50
02/20/17
13:50
Periodicals
Restaurant Brands in advanced talks to buy Popeyes, Bloomberg says »

A deal could be announced…

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

PLKI

Popeyes

$66.12

-0.26 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

AAPL

Apple

$135.72

0.375 (0.28%)

, AMAT

Applied Materials

$35.67

0.49 (1.39%)

13:48
02/20/17
02/20
13:48
02/20/17
13:48
Periodicals
Smartphone design trends could benefit Applied Materials, others, Barron's says »

As Apple (AAPL) and other…

AAPL

Apple

$135.72

0.375 (0.28%)

AMAT

Applied Materials

$35.67

0.49 (1.39%)

OLED

Universal Display

$72.15

0.85 (1.19%)

GLW

Corning

$27.65

-0.06 (-0.22%)

SSNLF

Samsung

LPL

LG Display

$12.39

0.07 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 13

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

  • 28

    Mar

  • 01

    Apr

TOSBF

Toshiba, also use TOSYY

$1.61

-0.182 (-10.17%)

, TOSYY

Toshiba, also use TOSBF

$9.55

-1.085 (-10.21%)

13:32
02/20/17
02/20
13:32
02/20/17
13:32
Periodicals
Toshiba could have 50% upside, Barron's says »

Toshiba shares are…

TOSBF

Toshiba, also use TOSYY

$1.61

-0.182 (-10.17%)

TOSYY

Toshiba, also use TOSBF

$9.55

-1.085 (-10.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIN

DineEquity

$60.14

-6.41 (-9.63%)

13:27
02/20/17
02/20
13:27
02/20/17
13:27
Periodicals
DineEquity remains challenged, Barron's says »

"Problems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

HD

Home Depot

$143.00

1.46 (1.03%)

13:09
02/20/17
02/20
13:09
02/20/17
13:09
Periodicals
Home Depot looks healthy into earnings report, Barron's says »

Home Depot remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 15

    Mar

ADNT

Adient

$64.01

-0.69 (-1.07%)

, JCI

Johnson Controls

$41.91

0.23 (0.55%)

12:58
02/20/17
02/20
12:58
02/20/17
12:58
Periodicals
Adient could offer 35% upside, Barron's says »

Shares of Adient (ADNT)…

ADNT

Adient

$64.01

-0.69 (-1.07%)

JCI

Johnson Controls

$41.91

0.23 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$51.75

0.45 (0.88%)

12:47
02/20/17
02/20
12:47
02/20/17
12:47
Periodicals
Steer clear of Hess Corp, Barron's says »

Hess Corp shares are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

GM

General Motors

$37.22

0.19 (0.51%)

12:33
02/20/17
02/20
12:33
02/20/17
12:33
Periodicals
General Motors stock could reach $50 in a year, Barron's says »

Shares of General Motors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

11:43
02/20/17
02/20
11:43
02/20/17
11:43
Conference/Events
DA Davidson E&C and industrials analysts hold analyst/industry conference call »

E&C, Materials &…

11:38
02/20/17
02/20
11:38
02/20/17
11:38
Conference/Events
DA Davidson technology/software analysts hold analyst/industry conference call »

Technology Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.